Lassa

Batavia Biosciences announced last week that it has successfully manufactured shots for Phase 1 trials in Africa and the U.S. of the recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine being developed by the International AIDS Vaccine Initiative (IAVI).

The Dutch company, which initially partnered with IAVI in 2018, said it manufactured rVSVΔG-LASV-GPC using its HIP-Vax platform, which “enables the production of high volumes of vaccine doses in a small…

The International AIDS Vaccine Initiative (IAVI) announced Monday $27.4 million in additional funding to conduct Phase 2b trials of its recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine (rVSVΔG-LASV-GPC) in Liberia, Nigeria and Sierra Leone.

According to the press release, the European & Developing Countries Clinical Trials Partnership and the Coalition for Epidemic Preparedness Innovations (CEPI) provided the grant, which builds on an earlier $10.4…

Mentions:

The Coalition for Epidemic Preparedness Innovations (CEPI) released a $3.5 billion investment case on Wednesday, outlining a five-year plan that includes a “moonshot” objective: compressing vaccine development timelines to 100 days.

Among the plan’s other goals are developing vaccines for known threats (such as chikungunya, Lassa fever and Nipah), producing a “library of prototype vaccines” from critical viral families, and supporting vaccine manufacturing in low- and middle-income…

Inovio announced Tuesday that it has dosed the first participant in a West Africa-based Phase 1b trial of its INO-4500 DNA vaccine against Lassa fever.

The Pennsylvania-based company said it hopes to make the shot available for emergency use “as [a] stockpile product following Phase 2.” The candidate—delivered through Inovio’s Cellectra “smart device”—generated robust antibody and T cell immune responses in previous U.S.-based Phase 1 trials, the press release noted.

The…

Mentions:

The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a $26 million West African Lassa fever research program, a coalition press release said last week.

Up to 23,000 participants across outbreak-prone Benin, Guinea, Liberia, Nigeria and Sierra Leone will take part over the next 24 months in “Enable”—the largest Lassa fever research program in the region to date, according to CEPI.

Findings from Enable will guide decisions on the design of future late-stage…

Atlanta-based GeoVax announced Monday that it has signed a licensing agreement with the U.S. National Institute of Allergy and Infectious Diseases to support the company’s nonclinical development of vaccines against Ebola Sudan, Ebola Zaire, Lassa virus, malaria, Marburg virus and Zika virus, among other diseases.

The agreement—which also boosts the company’s oncology portfolio—gives GeoVax nonexclusive “access to certain materials and patent rights,” according to the press release.

The Lancet Infectious Diseases published Phase 1 results last week showing that Profectus Bio’s vesicular stomatitis virus-based Zaire ebolavirus vaccine proved immunogenic in humans and produced fewer side effects than Merck’s Ervebo.

Maryland-based Profectus is also developing an investigational quadrivalent vaccine against Marburg, Lassa and two Ebola strains.

CureVac announced positive interim results yesterday from Phase 1 trials of its novel prophylactic messenger RNA-based rabies vaccine.

The German biotech said two administrations of a low dose of CV7202 demonstrated a “strong adaptive immune response with protective virus-neutralizing antibody titers levels above the threshold recommended” by WHO and that the vaccine schedule was well-tolerated.

CureVac is also developing prophylactic and therapeutic mRNA vaccines for cancers,…

India’s Aurobindo announced in a filing last week that its U.S. vaccines subsidiary will acquire $11.3 million of R&D assets from Maryland-based Profectus BioSciences. The company disclosed few details, but the filing noted that Profectus stands to earn milestone payments.

The Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. National Institute of Allergy and Infectious Diseases (NIAID) are among the funders of Profectus, a clinical-stage vaccine developer working…

The International AIDS Vaccine Initiative (IAVI) announced yesterday that the U.S. Defense Threat Reduction Agency (DTRA) is giving it $35.7 million to develop a recombinant vesicular stomatitis virus (VSV) vector Marburg vaccine. A separate press release from Netherlands-based Batavia Biosciences said it will work with IAVI on the project.

Meanwhile, in other Marburg news, the U.S. National Institutes of Health announced last week that an investigational quadrivalent vaccine co-…